SATB2 is a novel marker of osteoblastic differentiation in bone and soft tissue tumours

Histopathology

Volumn 63, Issue 1, 2013, Pages 36-49

  Conner, James R ^a   Hornick, Jason L ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Chondrosarcoma; Immunohistochemistry; Liposarcoma; Osteosarcoma; SATB2; Soft tissue tumours; Transcription factor

Indexed keywords

BINDING PROTEIN; CELL MARKER; COLLAGEN; NUCLEAR MATRIX PROTEIN; SPECIAL AT RICH SEQUENCE BINDING PROTEIN 2; UNCLASSIFIED DRUG;

ARTICLE; BONE TUMOR; CANCER TISSUE; CELL DIFFERENTIATION; DIAGNOSTIC VALUE; FIBROUS DYSPLASIA; GIANT CELL TUMOR; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; OSTEOBLAST; OSTEOBLASTOMA; OSTEOID OSTEOMA; OSTEOSARCOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SOFT TISSUE TUMOR; SYNOVIAL SARCOMA; TISSUE SECTION;

BONE AND BONES; BONE NEOPLASMS; CELL DIFFERENTIATION; HUMANS; MATRIX ATTACHMENT REGION BINDING PROTEINS; OSTEOBLASTOMA; OSTEOBLASTS; OSTEOMA, OSTEOID; OSTEOSARCOMA; SARCOMA, SYNOVIAL; SOFT TISSUE NEOPLASMS; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84879463172     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12138     Document Type: Article

References (40)

1. Geller DS, Gorlick R. Osteosarcoma: a review of diagnosis, management, and treatment strategies. Clin. Adv. Hematol. Oncol. 2010; 8; 705-718.
2. Ritter J, Bielack SS. Osteosarcoma. Ann. Oncol. 2010; 21(Suppl. 7); vii 320-vii 325.
3. Fletcher CD, Hogendoorn P, Mertens F, Bridge J eds. World Health organization classification of tumours of soft tissue and bone. Lyon: IARC Press, 2013.
4. D'Adamo DR. Appraising the current role of chemotherapy for the treatment of sarcoma. Semin. Oncol. 2011; 38(Suppl. 3); S19-S29.
5. Wesolowski R, Budd GT. Use of chemotherapy for patients with bone and soft-tissue sarcomas. Cleve. Clin. J. Med. 2010; 77(Suppl. 1); S23-S26.
6. Schulz A, Jundt G. Immunohistological demonstration of osteonectin in normal bone tissue and in bone tumors. Curr. Top. Pathol. 1989; 80; 31-54.
7. Schulz A, Jundt G, Berghauser KH, Gehron-Robey P, Termine JD. Immunohistochemical study of osteonectin in various types of osteosarcoma. Am. J. Pathol. 1988; 132; 233-238.
8. Serra M, Scotlandi K, Sollazzo M et al. Value of immunohistochemical detection of noncollagenous proteins of bone for the diagnosis of bone tumours. Int. J. Oncol. 1996; 9; 257-261.
9. Wuisman P, Roessner A, Bosse A, Ueda Y, Winkelmann W, Enneking WF. Osteonectin in osteosarcomas: a marker for differential diagnosis and/or prognosis? Ann. Oncol. 1992; 3(Suppl. 2); S33-S35.
10. Inoue T, Hagiyama M, Enoki E et al. Cell adhesion molecule 1 is a new osteoblastic cell adhesion molecule and a diagnostic marker for osteosarcoma. Life Sci. 2013; 92; 91-99.
11. Hua Y, Jia X, Sun M et al. Plasma membrane proteomic analysis of human osteosarcoma and osteoblastic cells: revealing NDRG1 as a marker for osteosarcoma. Tumour Biol. 2011; 32; 1013-1021.
12. Zhang Z, Zhang L, Hua Y et al. Comparative proteomic analysis of plasma membrane proteins between human osteosarcoma and normal osteoblastic cell lines. BMC Cancer 2010; 10; 206.
13. Dancer JY, Henry SP, Bondaruk J et al. Expression of master regulatory genes controlling skeletal development in benign cartilage and bone forming tumors. Hum. Pathol. 2010; 41; 1788-1793.
14. Horvai AE, Roy R, Borys D, O'Donnell RJ. Regulators of skeletal development: a cluster analysis of 206 bone tumors reveals diagnostically useful markers. Mod. Pathol. 2012; 25; 1452-1461.
15. Sheehan-Rooney K, Palinkasova B, Eberhart JK, Dixon MJ. A cross-species analysis of SATB2 expression suggests deep conservation across vertebrate lineages. Dev. Dyn. 2010; 239; 3481-3491.
16. Dobreva G, Chahrour M, Dautzenberg M et al. Satb2 is a multifunctional determinant of craniofacial patterning and osteoblast differentiation. Cell 2006; 125; 971-986.
17. FitzPatrick DR, Carr IM, McLaren L et al. Identification of satb2 as the cleft palate gene on 2q32-q33. Hum. Mol. Genet. 2003; 12; 2491-2501.
18. Leoyklang P, Suphapeetiporn K, Siriwan P et al. Heterozygous nonsense mutation SATB2 associated with cleft palate, osteoporosis, and cognitive defects. Hum. Mutat. 2007; 28; 732-738.
19. Rosenfeld JA, Ballif BC, Lucas A et al. Small deletions of SATB2 cause some of the clinical features of the 2q33.1 microdeletion syndrome. PLoS ONE 2009; 4; e6568.
20. Urquhart J, Black GC, Clayton-Smith J. 4.5 Mb microdeletion in chromosome band 2q33.1 associated with learning disability and cleft palate. Eur. J. Med. Genet. 2009; 52; 454-457.
21. Magnusson K, de Wit M, Brennan DJ et al. Satb2 in combination with cytokeratin 20 identifies over 95% of all colorectal carcinomas. Am. J. Surg. Pathol. 2011; 35; 937-948.
22. Eberhard J, Gaber A, Wangefjord S et al. A cohort study of the prognostic and treatment predictive value of SATB2 expression in colorectal cancer. Br. J. Cancer 2012; 106; 931-938.
23. Link MP, Goorin AM, Horowitz M et al. Adjuvant chemotherapy of high-grade osteosarcoma of the extremity. Updated results of the multi-institutional osteosarcoma study. Clin. Orthop. Relat. Res. 1991; 270; 8-14.
24. Meyers PA, Schwartz CL, Krailo M et al. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J. Clin. Oncol. 2005; 23; 2004-2011.
25. Grier HE, Krailo MD, Tarbell NJ et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N. Engl. J. Med. 2003; 348; 694-701.
26. Hustu HO, Pinkel D, Pratt CB. Treatment of clinically localized Ewing's sarcoma with radiotherapy and combination chemotherapy. Cancer 1972; 30; 1522-1527.
27. Jurgens H, Exner U, Gadner H et al. Multidisciplinary treatment of primary Ewing's sarcoma of bone. A 6-year experience of a European cooperative trial. Cancer 1988; 61; 23-32.
28. Nesbit ME Jr, Gehan EA, Burgert EO Jr. et al. Multimodal therapy for the management of primary, nonmetastatic Ewing's sarcoma of bone: a long-term follow-up of the first intergroup study. J. Clin. Oncol. 1990; 8; 1664-1674.
29. Dickey ID, Rose PS, Fuchs B et al. Dedifferentiated chondrosarcoma: the role of chemotherapy with updated outcomes. J. Bone Joint Surg. Am. 2004; 86A; 2412-2418.
30. Grimer RJ, Gosheger G, Taminiau A et al. Dedifferentiated chondrosarcoma: prognostic factors and outcome from a European group. Eur. J. Cancer 2007; 43; 2060-2065.
31. Staals EL, Bacchini P, Bertoni F. Dedifferentiated central chondrosarcoma. Cancer 2006; 106; 2682-2691.
32. Evans HL, Khurana KK, Kemp BL, Ayala AG. Heterologous elements in the dedifferentiated component of dedifferentiated liposarcoma. Am. J. Surg. Pathol. 1994; 18; 1150-1157.
33. Henricks WH, Chu YC, Goldblum JR, Weiss SW. Dedifferentiated liposarcoma: a clinicopathological analysis of 155 cases with a proposal for an expanded definition of dedifferentiation. Am. J. Surg. Pathol. 1997; 21; 271-281.
34. Huang W, Yang S, Shao J, Li YP. Signaling and transcriptional regulation in osteoblast commitment and differentiation. Front. Biosci. 2007; 12; 3068-3092.
35. Fanburg JC, Rosenberg AE, Weaver DL et al. Osteocalcin and osteonectin immunoreactivity in the diagnosis of osteosarcoma. Am. J. Clin. Pathol. 1997; 108; 464-473.
36. Fanburg-Smith JC, Bratthauer GL, Miettinen M. Osteocalcin and osteonectin immunoreactivity in extraskeletal osteosarcoma: a study of 28 cases. Hum. Pathol. 1999; 30; 32-38.
37. Doyle LA, Hornick JL. Immunohistology of soft tissue and osseous neoplasms. In Dabbs DJ ed. Diagnostic immunohistochemistry: theranostic and genomic applications. Philadelphia, PA: Saunders/Elsevier, 2013.
38. Goldring SR, Roelke MS, Petrison KK, Bhan AK. Human giant cell tumors of bone identification and characterization of cell types. J. Clin. Invest. 1987; 79; 483-491.
39. Salerno M, Avnet S, Alberghini M, Giunti A, Baldini N. Histogenetic characterization of giant cell tumor of bone. Clin. Orthop. Relat. Res. 2008; 466; 2081-2091.
40. Park HR, Park YK, Jang KT, Unni KK. Expression of collagen type II, s100b, s100a2 and osteocalcin in chondroblastoma and chondromyxoid fibroma. Oncol. Rep. 2002; 9; 1087-1091.